Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

MS Drugs Ocrevus and Gilenya Linked to Melanoma, Other Skin Cancers

April 15, 2022 By Law Offices of Thomas J. Lamb, P.A.

Multiple sclerosis (MS) drugs Ocrevus and Gilenya have been linked to melanoma, with Gilenya linked to squamous cell carcinoma and basal cell carcinoma, also. These new drug safety findings come from an analysis of skin cancer cases reported to the FDA Adverse Event Reporting System (FAERS) for patients receiving certain multiple sclerosis (MS) … [Read more...]

Filed Under: Unsafe Drugs Tagged With: basal cell carcinoma, Gilenya, Lemtrada, Mayzent, melanoma skin cancer, Ocrevus, skin cancers, squamous cell carcinoma

Lemtrada Side Effects Now Include Lemtrada Causing ANCA-Associated Vasculitis

April 30, 2020 By Law Offices of Thomas J. Lamb, P.A.

Lemtrada causing ANCA-associated vasculitis adds to the growing number of autoimmune complications which can be regarded as Lemtrada side effects. Medical researchers in Switzerland recently presented the case of a 26-year-old man who developed life-threatening anti-neutrophil cytoplasmic autoantibody (ANCA) systemic vasculitis after being treated … [Read more...]

Filed Under: Unsafe Drugs Tagged With: ANCA-associated vasculitis, Lemtrada

Lemtrada-Related Cardiovascular Reactions And Immune-Mediated Reactions

March 18, 2020 By Law Offices of Thomas J. Lamb, P.A.

Lemtrada (alemtuzumab) is a monoclonal antibody (mAb) authorized for the treatment of adults with relapsing-remitting multiple sclerosis (MS). Some recent significant safety findings for this MS drug safety findings include Lemtrada cardiovascular reactions and Lemtrada immune-mediated reactions. The UK Medicines and Healthcare Products … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Autoimmune Hepatitis, immune-mediated thrombocytopenia, Lemtrada

Lemtrada Safety Issues Lead To Use Restrictions In Europe

November 26, 2019 By Law Offices of Thomas J. Lamb, P.A.

Drug safety regulators for the European Union recently recommended that Lemtrada use be restricted to certain limited patient populations due to serious side effects linked to Lemtrada. This November 5, 2019 Multiple Sclerosis News Today report, “EMA Safety Group Advises Lemtrada Be Limited to ‘Highly Active’ RRMS Patients at Hospitals … [Read more...]

Filed Under: Unsafe Drugs Tagged With: bleeding disorders, bleeding in the lungs, Heart Attacks, Hepatitis, Lemtrada, liver damage, Strokes

Lemtrada Adverse Events: Ten Deaths Related To Lemtrada, According To New Medical Journal Article

October 14, 2019 By Law Offices of Thomas J. Lamb, P.A.

Lemtrada adverse events (AEs) may occur more frequently than previously understood, according to an August 2019 medical journal article. This new Lemtrada drug safety information appeared in this article, “Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis”, published August 12, 2019 by BMC Research … [Read more...]

Filed Under: Unsafe Drugs Tagged With: agranulocytosis, Autoimmune Hepatitis, immune-mediated thrombocytopenia, intracerebral hemorrhage, Lemtrada, listeriosis, organ failure, pneumonia, septic shock

Lemtrada Drug Safety Update: Use Restrictions And Patient Monitoring For Side Effects

July 9, 2019 By Law Offices of Thomas J. Lamb, P.A.

On May 17, 2019 the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued this Lemtrada Drug Safety Update, “Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements”, we get this summary: While an urgent [European Union (EU)] safety … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Autoimmune Hepatitis, Heart Attacks, Lemtrada, Strokes

Lemtrada Side Effects Being Investigated By European Drug Regulatory Agency

April 29, 2019 By Law Offices of Thomas J. Lamb, P.A.

The multiple sclerosis drug Lemtrada (alemtuzumab) is under scrutiny from the European Medicines Agency (EMA), according to the drug regulator’s April 12, 2019 press release, “Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing”. From this April 14, 2019 Medscape article, “PRAC Restricts Use of Alemtuzumab for MS … [Read more...]

Filed Under: Unsafe Drugs Tagged With: cardiovascular events, Lemtrada, liver damage, pulmonary side effects

Lemtrada: Strokes, Arterial Dissections / Blood Vessel Lining Damage

December 10, 2018 By Law Offices of Thomas J. Lamb, P.A.

In November 2018 the FDA mandated Lemtrada label changes, which include an increased risk of strokes warning being added to the “Black-Box Warning” and a new part — 5.3 Stroke and Cervicocephalic Arterial Dissection — being added to the WARNINGS AND PRECAUTIONS section of the current Full Prescribing Information, or drug label, for … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Arterial Dissections, Blood Vessel Lining Damage, Lemtrada, Strokes

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.